"Normal" thrombin generation.
暂无分享,去创建一个
K. Mann | S. Butenas | C. Veer | C. van’t Veer | S Butenas | K G Mann | C van't Veer
[1] A. Zivelin,et al. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors. , 1993, The Journal of clinical investigation.
[2] P. Callas,et al. The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. , 1989, Blood.
[3] K. Mann,et al. The interaction of bovine factor V and factor V-derived peptides with phospholipid vesicles. , 1983, The Journal of biological chemistry.
[4] M. Makris,et al. Co-inheritance of the 20210A Allele of the Prothrombin Gene Increases the Risk of Thrombosis in Subjects with Familial Thrombophilia , 1997, Thrombosis and Haemostasis.
[5] K. Kurachi,et al. Targeted inactivation of the coagulation factor IX gene causes hemophilia B in mice. , 1998, Blood.
[6] W. Novotny. Tissue Factor Pathway Inhibitor , 1994, Seminars in thrombosis and hemostasis.
[7] M. Ogletree,et al. Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding. , 1993, The Journal of pharmacology and experimental therapeutics.
[8] K. Mann,et al. Coordinate binding of factor Va and factor Xa to the unstimulated platelet. , 1981, The Journal of biological chemistry.
[9] S. Béguin,et al. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[10] K. Mann,et al. Activation of human prothrombin by human prothrombinase. Influence of factor Va on the reaction mechanism. , 1987, The Journal of biological chemistry.
[11] J Jesty,et al. Mathematical analysis of activation thresholds in enzyme-catalyzed positive feedbacks: application to the feedbacks of blood coagulation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[12] C. Esmon,et al. The natural anticoagulant protein S is decreased in male smokers. , 1991, American heart journal.
[13] K. Mann,et al. A model for the tissue factor pathway to thrombin. II. A mathematical simulation. , 1994, Journal of Biological Chemistry.
[14] M. Trimble,et al. The antiphospholipid syndrome: prevalence among patients with stroke and transient ischemic attacks. , 1990, The American journal of medicine.
[15] J. Levin,et al. Familial Multiple Coagulation Factor Deficiencies , 1981, Seminars in thrombosis and hemostasis.
[16] D. Ginsburg,et al. Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V , 1996, Nature.
[17] L. Hoyer. Medical progress : hemophilia A , 1994 .
[18] K. Mann,et al. Isolation of functional human coagulation factor V by using a hybridoma antibody. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[19] R. Colman,et al. Heterogeneity of human factor V deficiency. Evidence for the existence of antigen-positive variants. , 1983, The Journal of clinical investigation.
[20] J. Mustard,et al. Preparation of Suspensions of Washed Platelets from Humans , 1972, British journal of haematology.
[21] P. Reitsma,et al. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. , 1996, Blood.
[22] M. Woodward,et al. EPIDEMIOLOGY OF COAGULATION FACTORS, INHIBITORS AND ACTIVATION MARKERS: THE THIRD GLASGOW MONICA SURVEY II. RELATIONSHIPS TO CARDIOVASCULAR RISK FACTORS AND PREVALENT CARDIOVASCULAR DISEASE , 1997, British journal of haematology.
[23] P. Callas,et al. An unknown genetic defect increases venous thrombosis risk, through interaction with protein C deficiency. , 1998, American journal of human genetics.
[24] P. Carmeliet,et al. Mice lacking factor VII develop normally but suffer fatal perinatal bleeding , 1997, Nature.
[25] F. Ofosu,et al. Maturation of the hemostatic system during childhood. , 1992, Blood.
[26] S. Stone,et al. Inhibitory mechanism of serpins. Interaction of thrombin with antithrombin and protease nexin 1. , 1995, Biochemistry.
[27] Susan G. Brown,et al. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor , 1989, Nature.
[28] K. Mann,et al. Blood clotting in minimally altered whole blood. , 1996, Blood.
[29] F R Rosendaal,et al. Risk of Myocardial Infarction Associated With Factor V Leiden or Prothrombin Interaction of Coagulation Defects and Cardiovascular Risk Factors : Increased , 1998 .
[30] C. Esmon,et al. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. , 1984, The New England journal of medicine.
[31] K. Mann,et al. A model for the tissue factor pathway to thrombin. I. An empirical study. , 1994, The Journal of biological chemistry.
[32] M. Verstraete. Modulating platelet function with selective thrombin inhibitors. , 1996, Haemostasis.
[33] S. Özsoylu,et al. Acquired factor IX deficiency. A report of two cases. , 1973 .
[34] B. Brenner,et al. Hereditary deficiency of all vitamin K‐dependent procoagulants and anticoagulants , 1990, British journal of haematology.
[35] P. Reitsma,et al. Homozygosity for a Novel Missense Mutation in the Prothrombin Gene Causing a Severe Bleeding Disorder , 1994, Thrombosis and Haemostasis.
[36] M. Griffith,et al. Reactive site peptide structural similarity between heparin cofactor II and antithrombin III. , 1985, The Journal of biological chemistry.
[37] R. Carrell,et al. The incidence of dysfunctional antithrombin variants: four cases in 210 patients with thromboembolic disease , 1991, British journal of haematology.
[38] M. Ragni,et al. Factor VII deficiency , 1981, American journal of hematology.
[39] K. Mann,et al. "Clotspeed," a mathematical simulation of the functional properties of prothrombinase. , 1984, The Journal of biological chemistry.
[40] F F Costa,et al. Prevalence of the Prothrombin Gene Variant (nt20210A) in Venous Thrombosis and Arterial Disease , 1997, Thrombosis and Haemostasis.
[41] K. Mann,et al. Evaluation of the Initiation Phase of Blood Coagulation Using Ultrasensitive Assays for Serine Proteases* , 1997, The Journal of Biological Chemistry.
[42] L. Mattsson,et al. Haemostatic changes during continuous oestradiol-progestogen treatment of postmenopausal women. , 1991, British journal of obstetrics and gynaecology.
[43] K. Mann,et al. The regulation of clotting factors. , 1997, Critical reviews in eukaryotic gene expression.
[44] S. Rapaport,et al. A simplified procedure for purification of human prothrombin, factor IX and factor X. , 1981, Preparative biochemistry.
[45] J. Griffin,et al. Plasma protein S deficiency in familial thrombotic disease. , 1984, Blood.
[46] R. Lundblad,et al. Structure and function of factor IX: defects in haemophilia B. , 1985, Clinics in haematology.
[47] B. Coller,et al. Deficiency of Plasma Protein S, Protein C, or Antithrombin III and Arterial Thrombosis , 1987, Arteriosclerosis.
[48] C. Mcmillan,et al. Congenital combined deficiency of coagulation factors II, VII, IX and X. Report of a case. , 1966, The New England journal of medicine.
[49] T. Perneger,et al. Superficial Vein Thrombosis of Lower Limbs: Influence of Factor V Leiden, Factor II G20210A and Overweight , 1998, Thrombosis and Haemostasis.
[50] H. Niessner,et al. Coagulation Abnormalities in Liver Disease , 2008, Seminars in thrombosis and hemostasis.
[51] E. Beltrami,et al. Mathematical analysis of a proteolytic positive-feedback loop: dependence of lag time and enzyme yields on the initial conditions and kinetic parameters. , 1993, Biochemistry.
[52] D. Tollefsen,et al. Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. , 1982, The Journal of biological chemistry.
[53] M. Wardell,et al. Inhibitory mechanism of serpins , 1997 .
[54] P. Powers,et al. Development of the human coagulation system in the full-term infant. , 1987, Blood.
[55] J. Miletich,et al. Absence of thrombosis in subjects with heterozygous protein C deficiency. , 1987, The New England journal of medicine.
[56] Kenneth G. Mann,et al. Inhibitory Mechanism of the Protein C Pathway on Tissue Factor-induced Thrombin Generation , 1997, The Journal of Biological Chemistry.
[57] D. Tollefsen,et al. Heparin cofactor II. , 1997, Advances in experimental medicine and biology.
[58] K. Duffin,et al. Heterogeneity of plasma tissue factor pathway inhibitor. , 1994, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[59] K. Mann,et al. Blood coagulation in hemophilia A and hemophilia C. , 1998, Blood.
[60] Kenneth G. Mann,et al. Regulation of Tissue Factor Initiated Thrombin Generation by the Stoichiometric Inhibitors Tissue Factor Pathway Inhibitor, Antithrombin-III, and Heparin Cofactor-II* , 1997, The Journal of Biological Chemistry.
[61] B. Dahlbäck. Purification of human vitamin K-dependent protein S and its limited proteolysis by thrombin. , 1983, The Biochemical journal.
[62] D. Rosenthal. Recurrent venous thromboembolism in patients with a partial deficiency of protein S: Comp PC, Esmon CT. N Engl J Med 1984;311:1525–1528 , 1985 .
[63] G. Salvesen,et al. Human plasma proteinase inhibitors. , 1983, Annual review of biochemistry.
[64] K. Mann,et al. Regulation of Prothrombinase Activity by Protein S , 1999, Thrombosis and Haemostasis.
[65] C. Esmon,et al. Protein S deficiency occurs in the nephrotic syndrome. , 1987, Annals of internal medicine.
[66] L. Mattsson,et al. Haemostatic changes during continuous oestradiolprogestogen treatment of postmenopausal women , 1990 .
[67] R. Bertina,et al. Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. , 1983, The New England journal of medicine.
[68] Y Komiyama,et al. Proteolytic activation of human factors IX and X by recombinant human factor VIIa: effects of calcium, phospholipids, and tissue factor. , 1990, Biochemistry.
[69] P. Walsh. Platelet coagulant activities and hemostasis: a hypothesis. , 1974, Blood.
[70] K. Mann,et al. Increased Tissue Factor-initiated Prothrombin Activation as a Result of the Arg506 → Gln Mutation in Factor VLEIDEN * , 1997, The Journal of Biological Chemistry.
[71] J. T. ten Cate,et al. Clinical applications of new antithrombotic agents , 1996, Annals of Hematology.